A Phase 3 interventional study of losartan potassium in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 31st largest by enrollment, is one of 2 that started in 2009, is one of 17 in phase 3, and was the 14th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 6 Months to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is close to the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
26 studies in Hypertension by Organon & Co.: none open now, none under way, none of them phase 3. Of 26 finished, 15 (58%) have results posted.
Among the 26 studies in Hypertension by Organon & Co., this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2009, is one of 16 in phase 3, and was the 17th registered.
Organon & Co.’s Hypertension studies by the year they started, since 1995.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 26 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will explore the dose-response of losartan as well as the safety and tolerability in children from 6 months to 6 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
Drug: losartan potassium
Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
Drug: losartan potassium
Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
Drug: losartan potassium
losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
Also known as: Cozaar
Mean Change From Baseline in Systolic Blood Pressure
Sitting blood pressure (\[BP\] or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Systolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.
Time frame: Baseline and Day 21
Number of Participants Who Reported 1 or More Clinical and/or Laboratory Adverse Event(s)
Time frame: up to 12 weeks (Base Study); up to 24 months (Extension)
Number of Participants Who Were Discontinued From Study Due to a Clinical and/or Laboratory Adverse Event
Time frame: up to 12 weeks (Base Study); up to 24 months (Extension)
Mean Change From Baseline in Diastolic Blood Pressure
Sitting BP (or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Diastolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.
Time frame: Baseline and Day 21
| Milestone | Losartan Potassium 0.1 to 1.4 mg/kg | Losartan Potassium 0.3 to 1.4 mg/kg | Losartan Potassium 0.7 to 1.4 mg/kg | Losartan Potassium-Extension |
|---|---|---|---|---|
| Started | 33 | 34 | 34 | 0 |
| Completed | 31 | 34 | 32 | 0 |
| Not completed | 2 | 0 | 2 | 0 |
| Withdrew: Protocol-specific criteria met | 1 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Milestone | Losartan Potassium 0.1 to 1.4 mg/kg | Losartan Potassium 0.3 to 1.4 mg/kg | Losartan Potassium 0.7 to 1.4 mg/kg | Losartan Potassium-Extension |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 90 |
| Completed | 0 | 0 | 0 | 53 |
| Not completed | 0 | 0 | 0 | 37 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: End of study | 0 | 0 | 0 | 11 |
| Withdrew: Protocol-specific criteria met | 0 | 0 | 0 | 9 |
| Withdrew: Physician decision | 0 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 10 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
Sitting blood pressure (\[BP\] or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Systolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.
| mmHg | Losartan Potassium 0.1 to 1.4 mg/kg | Losartan Potassium 0.3 to 1.4 mg/kg | Losartan Potassium 0.7 to 1.4 mg/kg |
|---|---|---|---|
| Mean Change From Baseline in Systolic Blood Pressure | -7.31 ± 12.53 | -7.65 ± 7.49 | -6.67 ± 7.86 |
Sitting BP (or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Diastolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.
| mmHg | Losartan Potassium 0.1 to 1.4 mg/kg | Losartan Potassium 0.3 to 1.4 mg/kg | Losartan Potassium 0.7 to 1.4 mg/kg |
|---|---|---|---|
| Mean Change From Baseline in Diastolic Blood Pressure | -8.25 ± 11.76 | -5.15 ± 8.06 | -6.73 ± 8.59 |
| Participants | Base Study-Losartan Potassium 0.1 mg/kg | Base Study-Losartan Potassium 0.3 mg/kg | Base Study-Losartan Potassium 0.7 mg/kg | Base Study-Losartan Potassium 1.4 mg/kg | Extension-Losartan Potassium |
|---|---|---|---|---|---|
| Clinical Adverse Event | 21 | 30 | 36 | 22 | 75 |
| Laboratory Adverse Event | 1 | 1 | 0 | 0 | 5 |
| Participants | Base Study-Losartan Potassium 0.1 mg/kg | Base Study-Losartan Potassium 0.3 mg/kg | Base Study-Losartan Potassium 0.7 mg/kg | Base Study-Losartan Potassium 1.4 mg/kg | Extension-Losartan Potassium |
|---|---|---|---|---|---|
| Clinical Adverse Event | 0 | 0 | 0 | 0 | 1 |
| Laboratory Adverse Event | 0 | 0 | 0 | 0 | 0 |
Collected over up to 12 weeks (Base Study); up to 24 months (Extension). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study-Losartan Potassium 0.1 mg/kg/Day | — | 3/34 (8.8%) | 15/34 (44.1%) |
| Base Study-Losartan Potassium 0.3 mg/kg/Day | — | 2/54 (3.7%) | 22/54 (40.7%) |
| Base Study-Losartan Potassium 0.7 mg/kg/Day | — | 2/63 (3.2%) | 23/63 (36.5%) |
| Base Study-Losartan 1.4 mg/kg/Day | — | 0/33 (0%) | 17/33 (51.5%) |
| Extension-Losartan 0.1 mg/kg/Day | — | 3/15 (20%) | 12/15 (80%) |
| Extension-Losartan 0.3 mg/kg/Day | — | 5/28 (17.9%) | 20/28 (71.4%) |
| Extension-Losartan 0.7 mg/kg/Day | — | 2/31 (6.5%) | 20/31 (64.5%) |
| Extension-Losartan 1.4 mg/kg/Day | — | 5/42 (11.9%) | 28/42 (66.7%) |
| Event | Base Study-Losartan Potassium 0.1 mg/kg/Day | Base Study-Losartan Potassium 0.3 mg/kg/Day | Base Study-Losartan Potassium 0.7 mg/kg/Day | Base Study-Losartan 1.4 mg/kg/Day | Extension-Losartan 0.1 mg/kg/Day | Extension-Losartan 0.3 mg/kg/Day | Extension-Losartan 0.7 mg/kg/Day | Extension-Losartan 1.4 mg/kg/Day |
|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/34 | 0/54 | 0/63 | 0/33 | 0/15 | 2/28 | 1/31 | 1/42 |
| EnteritisGastrointestinal disorders | 0/34 | 0/54 | 0/63 | 0/33 | 1/15 | 0/28 | 0/31 | 0/42 |
| GastritisGastrointestinal disorders | 0/34 | 0/54 | 0/63 | 0/33 | 1/15 | 0/28 | 0/31 | 0/42 |
| Conjunctivitis bacterialInfections and infestations | 0/34 | 0/54 | 0/63 | 0/33 | 1/15 | 0/28 | 0/31 | 0/42 |
| NasopharyngitisInfections and infestations | 0/34 | 0/54 | 0/63 | 0/33 | 1/15 | 0/28 | 0/31 | 0/42 |
| SalmonellosisInfections and infestations | 0/34 | 0/54 | 0/63 | 0/33 | 1/15 | 0/28 | 0/31 | 0/42 |
| Upper respiratory tract infection bacterialInfections and infestations | 0/34 | 0/54 | 0/63 | 0/33 | 1/15 | 0/28 | 0/31 | 0/42 |
| DehydrationMetabolism and nutrition disorders | 0/34 | 0/54 | 0/63 | 0/33 | 0/15 | 1/28 | 0/31 | 0/42 |
| Metabolic acidosisMetabolism and nutrition disorders | 0/34 | 0/54 | 0/63 | 0/33 | 0/15 | 1/28 | 0/31 | 0/42 |
| NephroblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 0/54 | 0/63 | 0/33 | 0/15 | 1/28 | 0/31 | 0/42 |
| Event | Base Study-Losartan Potassium 0.1 mg/kg/Day | Base Study-Losartan Potassium 0.3 mg/kg/Day | Base Study-Losartan Potassium 0.7 mg/kg/Day | Base Study-Losartan 1.4 mg/kg/Day | Extension-Losartan 0.1 mg/kg/Day | Extension-Losartan 0.3 mg/kg/Day | Extension-Losartan 0.7 mg/kg/Day | Extension-Losartan 1.4 mg/kg/Day |
|---|---|---|---|---|---|---|---|---|
| PharyngitisInfections and infestations | 3/34 | 2/54 | 1/63 | 1/33 | 4/15 | 1/28 | 0/31 | 1/42 |
| DiarrhoeaGastrointestinal disorders | 2/34 | 3/54 | 4/63 | 2/33 | 3/15 | 3/28 | 5/31 | 6/42 |
| Urinary tract infectionInfections and infestations | 2/34 | 2/54 | 4/63 | 4/33 | 0/15 | 1/28 | 3/31 | 7/42 |
| NasopharyngitisInfections and infestations | 2/34 | 7/54 | 3/63 | 2/33 | 2/15 | 4/28 | 5/31 | 2/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/34 | 2/54 | 2/63 | 5/33 | 1/15 | 1/28 | 3/31 | 5/42 |
| PyrexiaGeneral disorders | 3/34 | 4/54 | 3/63 | 1/33 | 1/15 | 4/28 | 2/31 | 4/42 |
| Upper respiratory tract infectionInfections and infestations | 1/34 | 3/54 | 2/63 | 0/33 | 1/15 | 4/28 | 3/31 | 4/42 |
| ConjunctivitisEye disorders | 0/34 | 2/54 | 1/63 | 0/33 | 2/15 | 0/28 | 2/31 | 1/42 |
| Acute tonsillitisInfections and infestations | 0/34 | 0/54 | 0/63 | 0/33 | 2/15 | 1/28 | 1/31 | 0/42 |
| Respiratory tract infectionInfections and infestations | 2/34 | 1/54 | 5/63 | 3/33 | 2/15 | 3/28 | 3/31 | 5/42 |
| Age, Continuous(Months) | Losartan Potassium 0.1 to 1.4 mg/kg | Losartan Potassium 0.3 to 1.4 mg/kg | Losartan Potassium 0.7 to 1.4 mg/kg | Total |
|---|---|---|---|---|
| Mean | 40.2 ± 24.4 | 45.0 ± 21.5 | 40.6 ± 21.2 | 42.0 ± 22.3 |
| Sex: Female, Male(Participants) | Losartan Potassium 0.1 to 1.4 mg/kg | Losartan Potassium 0.3 to 1.4 mg/kg | Losartan Potassium 0.7 to 1.4 mg/kg | Total |
|---|---|---|---|---|
| Female | 13 | 16 | 14 | 43 |
| Male | 20 | 18 | 20 | 58 |
No study locations are listed for this record.
Plan to share: No
Ran from Mar 2009 to primary completion in Aug 2012, 41 months.
Results were first posted in Mar 2014, 1 year 6 months after primary completion. A results delay was requested in Aug 2013.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 41 months is above that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan